More recently, investigators have discovered that catechol-O-methyltransferase inhibitors can prolong the effects of levodopa, thereby limiting the off-time phenomenon.
Hannah Kent Ritchie, PhD
Advertisement
Articles by Hannah Kent Ritchie, PhD
Advertisement
Latest Updated Articles
FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer DiseasePublished: August 29th 2025 | Updated: September 2nd 2025
Indirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over DonanemabPublished: July 28th 2025 | Updated: July 30th 2025
Observed Differences in PIRA Definition Call for More Standardized Agreement on TermPublished: May 14th 2025 | Updated: May 16th 2025
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack SeverityPublished: May 12th 2025 | Updated: May 13th 2025
- FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion CountsPublished: March 4th 2025 | Updated: March 19th 2025
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Daridorexant Provides Relief for Insomnia in Women During Menopausal Transition
2
New Study Finds Link Between Gut Hormone GLP-1 and NMOSD Symptoms, Paving Way for Targeted Treatments
3
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
4
International Committee Publishes 2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis
5
